» Articles » PMID: 11073940

MEKK2 Associates with the Adapter Protein Lad/RIBP and Regulates the MEK5-BMK1/ERK5 Pathway

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2000 Nov 14
PMID 11073940
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

MEKK2 and MEKK3 are two closely related mitogen-activated protein kinase (MAPK) kinase kinases. The kinase domains of MEKK2 and MEKK3 are nearly identical, although their N-terminal regulatory domains are significantly divergent. By yeast two-hybrid library screening, we have identified MEK5, the MAPK kinase in the big mitogen-activated protein kinase 1 (BMK1)/ERK5 pathway, as a binding partner for MEKK2. MEKK2 expression stimulates BMK1/ERK5 activity, the downstream substrate for MEK5. Compared with MEKK3, MEKK2 activated BMK1/ERK5 to a greater extent, which might correlate with a higher affinity MEKK2-MEK5 interaction. A dominant negative form of MEK5 blocked the activation of BMK1/ERK5 by MEKK2, whereas activation of c-Jun N-terminal kinase (JNK) was unaffected, showing that MEK5 is a specific downstream effector of MEKK2 in the BMK1/ERK5 pathway. Activation of BMK1/ERK5 by epidermal growth factor and H2O2 in Cos7 and HEK293 cells was completely blocked by a kinase-inactive MEKK3 (MEKK3kin(-)), whereas MEKK2kin(-) had no effect. However, in D10 T cells, expression of MEKK2kin(-) but not MEKK3kin(-) inhibited BMK1/ERK5 activity. Two-hybrid screening also identified Lck-associated adapter/Rlk- and Itk-binding protein (Lad/RIBP), a T cell adapter protein, as a binding partner for MEKK2. MEKK2 and Lad/RIBP colocalize at the T cell contact site with antigen-loaded presenting cells, demonstrating cotranslocation of MEKK2 and Lad/RIBP during T cell activation. MEKK3 neither binds Lad/RIBP nor is recruited to the T cell contact with antigen presenting cell. MEKK2 and MEKK3 are differentially associated with signaling from specific upstream receptor systems, whereas both activate the MEK5-BMK1/ERK5 pathway.

Citing Articles

VEGF Stimulates Activation of ERK5 in the Absence of C-Terminal Phosphorylation Preventing Nuclear Localization and Facilitating AKT Activation in Endothelial Cells.

Mondru A, Aljasir M, Alrumayh A, Nithianandarajah G, Ahmed K, Muller J Cells. 2023; 12(6).

PMID: 36980305 PMC: 10047687. DOI: 10.3390/cells12060967.


ERK/MAPK signalling pathway and tumorigenesis.

Guo Y, Pan W, Liu S, Shen Z, Xu Y, Hu L Exp Ther Med. 2020; 19(3):1997-2007.

PMID: 32104259 PMC: 7027163. DOI: 10.3892/etm.2020.8454.


Beyond Kinase Activity: ERK5 Nucleo-Cytoplasmic Shuttling as a Novel Target for Anticancer Therapy.

Tubita A, Lombardi Z, Tusa I, Dello Sbarba P, Rovida E Int J Mol Sci. 2020; 21(3).

PMID: 32023850 PMC: 7038028. DOI: 10.3390/ijms21030938.


Targeting MEK5 impairs nonhomologous end-joining repair and sensitizes prostate cancer to DNA damaging agents.

Broustas C, Duval A, Chaudhary K, Friedman R, Virk R, Lieberman H Oncogene. 2020; 39(12):2467-2477.

PMID: 31980741 PMC: 7085449. DOI: 10.1038/s41388-020-1163-1.


IL-17R-EGFR axis links wound healing to tumorigenesis in Lrig1 stem cells.

Chen X, Cai G, Liu C, Zhao J, Gu C, Wu L J Exp Med. 2018; 216(1):195-214.

PMID: 30578323 PMC: 6314525. DOI: 10.1084/jem.20171849.